Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Verve Therapeutics

Main focus: Gene editing for the treatment of genetic cardiovascular diseases

Company stage: Pre-clinical

Diseases: Heterozygous familial hypercholesterolemia, familial hypercholesterolemia

Genome editing technology: Base editing, CRISPR-Cas9, CRISPR-Cas12a

Funding stage: Public (NASDAQ:VERV)

Location: Cambridge, MA, USA

Website: https://www.vervetx.com/

Pipeline: https://www.vervetx.com/pipeline/

Partners: Beam Therapeutics

Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The Broad Institute and has also licensed base-editing technology from Beam Therapeutics. The company is initially focusing on PCSK9 and ANGPTL3 as targets.

Tags

HashtagVerve Therapeutics, Inc.

Company: Verve Therapeutics
close
Search CRISPR Medicine